Provided by Tiger Trade Technology Pte. Ltd.

ACLARION, INC

2.75
+0.390016.53%
Post-market: 2.73-0.0219-0.80%19:53 EST
Volume:185.61K
Turnover:481.13K
Market Cap:2.90M
PE:0.00
High:2.82
Open:2.43
Low:2.41
Close:2.36
52wk High:229.50
52wk Low:2.34
Shares:1.05M
Float Shares:1.05M
Volume Ratio:0.86
T/O Rate:17.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1,597.9500
EPS(LYR):-8.8206
ROE:-97.72%
ROA:-52.37%
PB:0.23
PE(LYR):-0.31

Loading ...

Aclarion Inc - Has Cash Runway Into 2028

THOMSON REUTERS
·
Feb 05

Aclarion schließt Vereinbarung mit Source Healthcare zur Nutzung von Nociscan

Reuters
·
Feb 03

Aclarion Raises $10.4 Million, Sharpens Focus On Nociscan Rollout

Benzinga_recent_news
·
Jan 13

BRIEF-Aclarion Inc - Extends Cash Runway Into 2028 - SEC Filing

Reuters
·
Jan 13

Aclarion Inc trading halted, volatility trading pause

TIPRANKS
·
Jan 08

Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars

Benzinga_recent_news
·
Jan 08

Aclarion Launches CLARITY Trial to Advance Nociscan for Chronic Low Back Pain

Reuters
·
Jan 08

Aclarion Inc - Aims to Enroll 25% in Clarity Trial by Q2 2026

THOMSON REUTERS
·
Jan 08

Aclarion Provides 2025 Update and 2026 Corporate Outlook

THOMSON REUTERS
·
Jan 08

Aclarion Inc - Cash Resources Sufficient to Fund Operations Into 2027

THOMSON REUTERS
·
Jan 08

BRIEF-Aclarion Announces First Patient Enrollments At Two Additional Clarity Trial Sites

Reuters
·
Jan 06

Aclarion Inc - First Interim Data Readout Expected in 3Q 2026

THOMSON REUTERS
·
Jan 06

Aclarion Inc - Acclarion Targets Full Enrollmentof 300 Patients by Mid-2027

THOMSON REUTERS
·
Jan 06

Aclarion Announces First Patient Enrollments at Two Additional Clarity Trial Sites and Provides Guidance on Expected Availability of Initial Data

THOMSON REUTERS
·
Jan 06

Aclarion Launches CLARITY Trial with First Patients Enrolled at Leading Spine Centers

Reuters
·
Jan 06

Aclarion Nociscan Study Published in Leading Spine Surgery Journal

Reuters
·
Dec 04, 2025

Press Release: Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Dow Jones
·
Dec 02, 2025

Aclarion CEO Brent Ness Reports Acquisition of Common Shares

Reuters
·
Dec 02, 2025

Aclarion Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Nov 20, 2025

Aclarion Q3 EPS $(2.93) Misses $(2.62) Estimate, Sales $18.942K Miss $40.000K Estimate

Benzinga
·
Nov 12, 2025